Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Other Non Operating Income (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Other Non Operating Income for 4 consecutive years, with -$30000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 63.86% to -$30000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38000.0 through Dec 2025, up 272.73% year-over-year, with the annual reading at -$291000.0 for FY2025, 1718.75% down from the prior year.
  • Other Non Operating Income hit -$30000.0 in Q4 2025 for Taysha Gene Therapies, down from $292000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $100.5 million in Q3 2023 to a low of -$1.4 million in Q4 2023.
  • Historically, Other Non Operating Income has averaged $6.6 million across 4 years, with a median of -$6000.0 in 2022.
  • Biggest YoY gain for Other Non Operating Income was 10045700.0% in 2023; the steepest drop was 22800.0% in 2023.
  • Year by year, Other Non Operating Income stood at -$6000.0 in 2022, then plummeted by 22800.0% to -$1.4 million in 2023, then soared by 93.96% to -$83000.0 in 2024, then surged by 63.86% to -$30000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for TSHA at -$30000.0 in Q4 2025, $292000.0 in Q3 2025, and -$237000.0 in Q2 2025.